ProCE Banner Activity

Taking Control in Moderate to Severe Atopic Dermatitis: Expert Guidance for Advancing Treatment With Biologic Therapies Targeting the IL-4/IL-13 and IL-13 Axis

Slideset

Expert-curated slides on the disease assessment of atopic dermatitis to monitor treatment response and recognize opportunities to advance therapy to improve disease control while competently applying expert guidance, available evidence, and clinical rationale.

Released: April 09, 2025

Expiration: April 08, 2026

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

Practicing Clinicians Exchange

ProCE Banner

Faculty Disclosure

Primary Author

Peter Lio, MD, FAAD: consultant/advisor/speaker: AbbVie, Almirall, Alphyn Biologics, Amyris, Arcutis, Bristol Myers Squibb, Codex Labs, Concerto Biosciences, Dermavant, Eli Lilly, Galderma, Hyphens Pharma, Incyte, Janssen, La Roche-Posay/L'Óreal, LEO Pharma, Micreos, MyOR Diagnostics, Pelthos Therapeutics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, Skinfix, Soteri Skin, Stratum Biosciences, Thimble Health, UCB, Verdant Scientific, Verrica, Yobee Care; individually publicly traded stocks/stock options: Alphyn Biologics, Codex Labs, Concerto Biosciences, Soteri Skin, Stratum Biosciences, Thimble, Verdant Scientific, Yobee Care; royalties/patent beneficiary: Theraplex AIM (patent pending).